Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.

Atsushi Tanaka,Takumi Imai,Michio Shimabukuro,Ikuko Nakamura,Kazuo Matsunaga,Yukio Ozaki,Tohru Minamino,Masataka Sata,Koichi Node

Journal of diabetes investigation（2022）

引用 0|浏览2

暂无评分

摘要

Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure.

查看译文

关键词

Chronic heart failure,Sodium-glucose cotransporter 2 inhibitor,White blood cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要